2 assets in Ovarian Clear Cell Malignant Adenofibroma

Therapeutic assets addressing Ovarian Clear Cell Malignant Adenofibroma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Ovarian Clear Cell Malignant Adenofibroma	National Cancer Institute (NCI)	P3	B (60)
Docetaxel Ovarian Clear Cell Malignant Adenofibroma	National Cancer Institute (NCI)	P3	B (60)